Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Lexicon Pharmaceuticals' share price has recently surpassed its 200-day moving average of $0.74, trading as high as $1.16.
• Analysts have optimistic views, with a majority rating the stock as a "Moderate Buy" and an average target price of $3.23.
• The company reported earnings of $0.01 per share for the last quarter, beating consensus estimates by $0.09, along with a revenue of $28.87 million compared to expectations of $4.87 million.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.74 and traded as high as $1.16. Lexicon Pharmaceuticals shares last traded at $1.14, with a volume of 908,019 shares trading hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LXRX shares. HC Wainwright reissued a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, June 24th. Citigroup lifted their price target on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a "buy" rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $3.23.

Lexicon Pharmaceuticals Stock Down 4.3%

The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.16 and a current ratio of 4.16. The stock has a market cap of $399.74 million, a price-to-earnings ratio of -3.33 and a beta of 1.26. The firm's 50-day simple moving average is $1.08 and its two-hundred day simple moving average is $0.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $28.87 million during the quarter, compared to analysts' expectations of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. On average, sell-side analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $38,000. Deutsche Bank AG grew its position in shares of Lexicon Pharmaceuticals by 378.0% during the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 249,616 shares during the period. Tang Capital Management LLC grew its position in shares of Lexicon Pharmaceuticals by 750.3% during the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company's stock worth $628,000 after buying an additional 750,268 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Northern Trust Corp grew its position in shares of Lexicon Pharmaceuticals by 14.4% during the 4th quarter. Northern Trust Corp now owns 1,308,651 shares of the biopharmaceutical company's stock worth $966,000 after buying an additional 164,620 shares during the period. Institutional investors and hedge funds own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.